NVS - Novartis Precision Cancer Therapy Hits Primary Goal In Rare Type Of Pancreatic Cancer | Benzinga
Novartis AG (NYSE: NVS) released topline data from the Phase 3 NETTER-2 trial with Lutathera, a radioligand therapy (RLT) for advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Radioligand therapy, or radionuclide or radiopharmaceutical therapy, is a targeted cancer treatment that delivers radiation directly to cancer cells. Radioligand therapy's precision helps limit damage to healthy, surrounding tissue.
The study met its primary endpoint of improvement in progression-free survival (PFS) and the key ...